N,N-Ru(ii)-p-cymene-poly(N-vinylpyrrolidone) surface functionalized gold nanoparticles: from organoruthenium complex to nanomaterial for antiproliferative activity

2021 ◽  
Author(s):  
Durairaj Gopalakrishnan ◽  
S. Saravanan ◽  
Ronald Merckx ◽  
Arumugam Madan Kumar ◽  
Themmila Khamrang ◽  
...  

The first report of a Ru(arene)metallopolymer–gold nanoconjugate to enhance the in vitro anticancer activity of Ru–arene complex in colorectal cancer cells.

2020 ◽  
Vol 44 (46) ◽  
pp. 20047-20059
Author(s):  
Durairaj Gopalakrishnan ◽  
Chezhiyan Sumithaa ◽  
Arumugam Madan Kumar ◽  
Nattamai S. P. Bhuvanesh ◽  
Suvankar Ghorai ◽  
...  

The first report of a Ru(arene)–liposome nanoaggregate to enhance the in vitro anticancer activity of a Ru–arene complex in liver cancer cells.


Materials ◽  
2020 ◽  
Vol 13 (2) ◽  
pp. 375 ◽  
Author(s):  
Raquel B. Liszbinski ◽  
Graziela G. Romagnoli ◽  
Carolina M. Gorgulho ◽  
Caroline R. Basso ◽  
Valber A. Pedrosa ◽  
...  

The aim of the current study is to present a strategy to improve the efficiency of 5-fluorouracil (5-FU), which is widely used as antineoplastic agent against solid tumors-based on the use of gold nanocarriers to overcome the resistance of colorectal cancer cells. 5-FU was loaded on gold nanoparticles (AuNP) coated with anti-EGFR antibodies in order to target them towards colorectal cancer cells that overexpress epidermal growth factor receptors (EGFR). Physicochemical characterization has shown that AuNP size was approximately 20 nm and that AuNP functionalization led to spherical nanoparticles. Flow cytometry allowed observing that some compounds synthesized by our research group have induced apoptosis/necrosis and impaired the proliferation of colon cancer cell lines ‘HCT-116′ and ‘HT-29′. The antibody/drug combination in AuNP (AuNP 5FU EGFR) has improved the apoptosis rate and impaired cell proliferation in both cell lines, regardless of the exposure time. Overall, these results have shown that AuNP functionalization with monoclonal antibodies focused on delivering 5-FU to tumor cells is an exciting strategy against colorectal cancer.


2020 ◽  
Author(s):  
Nakul Nautam Patel ◽  
Lucy Ghali ◽  
Ivan Roitt ◽  
Leonardo Pantoja Munoz ◽  
Richard Bayford

Abstract Colorectal cancer (CRC) is the fourth most common cancer in the world. Due to its asymptomatic nature, CRC is diagnosed at an advanced stage where the survival rate is <5%. Besides, prognosis from CRC treatment using chemotherapy, radiotherapy and surgery often causes undesirable side-effects. As such, gold nanoparticles (GNPs) are envisaged in the field for the diagnosis and treatment of CRC. GNPs have unique physical, chemical and electrical properties at nanoscale which makes them suitable for application in biomedicine. However, for GNPs to become clinically effective, its internalisation efficiency in the cancer cells must be enhanced. Folate receptor-α (FR) are overexpressed in CRC wherein FR helps in uptake of folic acid within the cell. Tyro3, a novel tyrosine kinase receptor, drives cell proliferation and its overexpression is correlated with poor prognosis in CRC. Their upregulated expression in CRC cells relative to normal cells makes them an ideal target for GNPs using active targeting. Therefore, in this study receptors FR and Tyro3 were simultaneously targeted using specific antibody-coated GNPs in order to enhance uptake and internalisation of GNPs in CRC cells in vitro. Four different types of coated-GNPs were synthesised GNPs-PEG, GNPs-anti-FR, GNPs-anti-Tyro3 and GNPs-anti-(FR+Tyro3) and incubated (0ng – 50ng) with three CRC cell lines including CRL1790, CRL2159 and HCT116. Simultaneous targeting of these receptors by GNPs-anti-(FR+Tyro3) was found to be the most effective in internalisation in CRC cells compared with GNPs targeted singly to FR or Tyro3 (p<0.05). Besides this, results show that Tyro3 mediated similar internalisation efficacy as FR (p<0.05) in CRC using ICP-OES.


2012 ◽  
Vol 48 ◽  
pp. S89
Author(s):  
J. de Freitas ◽  
L.G. Bastos ◽  
C.A. Freire-Neto ◽  
B.D.R. D'Aguiar-Silva ◽  
E.S. Abdelhay ◽  
...  

2012 ◽  
Vol 113 (9) ◽  
pp. 2957-2966 ◽  
Author(s):  
Julio Cesar Madureira de-Freitas-Junior ◽  
Lilian Golçalves Bastos ◽  
Carlos Alberto Freire-Neto ◽  
Bárbara Du Rocher ◽  
Eliana Saul Furquim Werneck Abdelhay ◽  
...  

2021 ◽  
Author(s):  
Nakul Nautam Patel ◽  
Lucy Ghali ◽  
Ivan Roitt ◽  
Leonardo Pantoja Munoz ◽  
Richard Bayford

Colorectal cancer (CRC) is the fourth most common cancer in the world. Due to its asymptomatic nature, CRC is diagnosed at an advanced stage where the survival rate is <5%....


2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Simona Mareike Lüttgenau ◽  
Christin Emming ◽  
Thomas Wagner ◽  
Julia Harms ◽  
Justine Guske ◽  
...  

AbstractLoss of apical-basal polarity and downregulation of cell-cell contacts is a critical step during the pathogenesis of cancer. Both processes are regulated by the scaffolding protein Pals1, however, it is unclear whether the expression of Pals1 is affected in cancer cells and whether Pals1 is implicated in the pathogenesis of the disease.Using mRNA expression data and immunostainings of cancer specimen, we show that Pals1 is frequently downregulated in colorectal cancer, correlating with poorer survival of patients. We further found that Pals1 prevents cancer cell metastasis by controlling Rac1-dependent cell migration through inhibition of Arf6, which is independent of the canonical binding partners of Pals1. Loss of Pals1 in colorectal cancer cells results in increased Arf6 and Rac1 activity, enhanced cell migration and invasion in vitro and increased metastasis of transplanted tumor cells in mice. Thus, our data reveal a new function of Pals1 as a key inhibitor of cell migration and metastasis of colorectal cancer cells. Notably, this new function is independent of the known role of Pals1 in tight junction formation and apical-basal polarity.


Sign in / Sign up

Export Citation Format

Share Document